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1. Introduction 
 
Chronic non-cancer pain (CNCP) is a common disorder that makes a major contribution to disease 
burden. The recent Global Burden of Disease 2010 study estimated that in 2010, low back pain, neck 
pain and migraines were the 1st, 4th and 8th largest contributors respectively to global non-fatal 
health burden (years lived with disability; Vos et al., 2012). CNCP also affects other domains, and can 
have a major adverse impact on social and ﬁnancial well-being, as well as health care costs (Beubler 
et al., 2006). With the ageing of the population in many high income countries, the burden of 
chronic pain is likely to increase in the future. 
Management of CNCP has been considered best through effective physical and psychological 
programmes, aided by non-opioid pharmacotherapy (Savage, 1999). Even when a combination of 
interventions is used, many people continue to experience pain that impairs daily functioning. Short-
term controlled trials have evaluated pharmaceutical opioids in the treatment of a range of CNCP 
conditions and have demonstrated modest attenuation of pain (Bloodworth, 2005); one systematic 
review concluded that there is only weak evidence of long-term analgesic beneﬁt (as deﬁned by 
improved physical function and quality of life) (Noble et al., 2010). 
There has been considerable debate about the role and efﬁcacy of cannabinoids for medicinal use in 
a range of CNCP conditions (Bostwick, 2014; Farrell et al., 2014; Robson, 2014). A recent review 
concluded that there is poor quality evidence of cannabinoid analgesic efﬁcacy from controlled trials 
of neuropathic pain associated with multiple sclerosis, spinal cord injury or HIV neuropathy (Farrell 
et al., 2014). Despite the limited data, there is strong advocacy by users for the symptomatic beneﬁt 
of adjunctive cannabis, and increasing general interest in its use. Although in most jurisdictions, 
doctors cannot prescribe cannabis despite requests from patients to do so, in countries where 
cannabis use may be legally obtained via either prescription or authorised by a medical practitioner, 
chronic pain is the most common indication for use [e.g., the Netherlands (Hazekamp and Heerdink, 
2013) and Canada (Ware et al., 2003)]. Although increasing numbers of US States are allowing the 
1 
 
Author postprint of Degenhardt, L., … & Hall, W. D. (2015). Experience of adjunctive cannabis use for 
chronic non-cancer pain: Findings from the Pain and Opioids IN Treatment (POINT) study. Drug 
Alcohol Depend 147, 144-150. 10.1016/j.drugalcdep.2014.11.031. Please refer to published version for 
tables mentioned in the text. 
 
medical use of cannabis, most recently including New York, in many places cannabis remains illegal 
for any purpose. Many CNCP patients have resorted to obtaining cannabis from the illicit market, 
risking the consequences of arrest and legal penalties (Lucas, 2009), and exposure to contaminants 
potentially worsening the medical condition. 
To date there have been few reports of patterns of use of cannabis for symptom control in chronic 
pain, whether initiated for this purpose or adapted for this use by recreational users (Ogborne et al., 
2000; Ware et al., 2003). There is also little information about the role of cannabis use as an adjunct 
to the use of opioids for pain control. Clearly, there is a need for studies of efﬁcacy of cannabis in the 
management of CNCP, both in its own right and as an adjunct to opioid use. In this paper, we use 
data from a national, community-based sample of people who have been prescribed opioids for 
their pain (Campbell et al., 2014b), to examine the extent to which cannabis is in fact used by this 
group. In Australia, as in many countries, there is no regulatory framework for medicinal cannabis or 
cannabinoid use, and cannabis possession and use are not legal. We speciﬁcally examined: 
 
1. The prevalence of non-medicinal use of cannabis and of cannabis use disorder; 
2. The prevalence and correlates of use of cannabis for pain; 
3. The association between cannabis use for pain, opioid dose and degree of interference from 
pain. 
 
2. Methods 
The Pain and Opioids IN Treatment (POINT) study includes 1514 people in Australia who have been 
prescribed opioids for chronic non-cancer pain; full details of the cohort and study design have been 
reported elsewhere (Campbell et al., 2014a,b). The study was approved by the Human Research 
Ethics Committee of the University of New South Wales (HREC reference: #HC12149). The study also 
received A1 Australian National Pharmacy Guild Approval to approach pharmacists to assist with 
recruitment of participants (Approval no. 815). 
POINT participants were 18 years or older; competent in English; and mentally and physically able to 
complete telephone and self-complete interviews; without serious cognitive impairments; living with 
chronic non-cancer pain; prescribed a Schedule 8 opioid (an Australian classiﬁcation that includes 
morphine, oxycodone, methadone, buprenorphine and fentanyl; Therapeutic Goods Administration, 
2013); and had been taking such opioids for CNCP for more than 6 weeks. A history of injecting drug 
use (IDU) was not an exclusion criterion, but those currently prescribed pharmaceutical opioids as 
opioid substitution therapy (OST) for heroin dependence were not eligible for inclusion. Persons 
taking opioids for cancer pain were excluded. A database of pharmacies and chemists across 
Australia (n = 5745) and their contact details was obtained. Pharmacies were allocated into a wave 
and successive waves contacted each week via fax to ascertain interest in assisting with study 
recruitment. Those who indicated they were interested in more information, or who did not respond 
to the fax were called and the study was explained to a pharmacist. 
Ninety-three percent of all pharmacies (n = 5332) were contacted, and 35% agreed to assist with 
recruitment (Campbell et al., 2014a,b). 
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Interested pharmacists were enrolled in the study for a six-week period. Pharmacists were asked to 
approach customers that were prescribed a Schedule 8 opioid for CNCP for a period of greater than 
6 weeks. Interested customers were given a ﬂyer about the study by the pharmacist, and either 
contacted the POINT team directly, or gave their name and phone number to the pharmacist, who 
sent details to researchers. Pharmacists were reimbursed $20 for each eligible participant they 
referred into the study (regardless of the person’s entry into the study). POINT staff determined the 
eligibility of those who were referred to the study, or who contacted the POINT team. Eligible 
participants who provided informed consent completed a baseline phone interview, which took 1–
1.5 h. 
 
2.1. Measures 
 
The domains assessed in the interview were based on recommendations made under the auspices of 
the Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT; Dworkin 
et al., 2005; Turk et al., 2003) to ensure we covered all areas recommended by this expert group. Full 
details of the speciﬁc measures used in the POINT baseline interview are described elsewhere 
(Campbell et al., 2014b). 
Questions on cannabis use for recreational purposes and for pain were included in the interview. 
Cannabis use disorders (ICD-10 harmful use and dependence) were assessed using the World Health 
Organization (WHO) Composite International Diagnostic Interview (CIDI) version 3.0 (Kessler and 
Ustun, 2004). 
Pain ratings and participant reports of pain relief were obtained using the Brief Pain Inventory (BPI; 
Tan et al., 2004). This was assessed as a continuous score out of 10 (with higher scores indicating 
greater pain severity/interference). The Pain Self Efﬁcacy Questionnaire was also used (Nicholas, 
2007; Nicholas et al., 2008); with lower score indicating poorer coping with pain. Participants were 
also asked if they suffered from incident pain (also termed “breakthrough pain”). 
Participants reported whether they were living with a range of chronic pain and physical health 
conditions. In order to facilitate ascertainment of pain conditions, a glossary of conditions that may 
lead to chronic pain was developed (see glossaries in Campbell et al. (2014b)). Questions were taken 
from the Chronic Conditions section of the CIDI 3.0 (Kessler and Ustun, 2004). Lifetime drug and 
alcohol use disorders (ICD-10 harmful use and dependence) were also assessed via the CIDI 3.0. 
Past two week depression and generalised anxiety disorder were measured by the PHQ-9 and GAD-7 
modules of the Pﬁzer Health Questionnaire (Kroenke et al., 2010). Previously validated cut-offs were 
used for screening tools as follows: symptoms indicating moderate to severe depression were 
deﬁned as a score of ≥10 on the PHQ-9 (Kroenke et al., 2001), symptoms of moderate to severe 
anxiety were deﬁned as a score of ≥10 on the GAD-7 (Spitzer et al., 2006). 
Participants were asked about current prescribed medications, with  examples being given for each 
class of medications examined. Detailed data on pharmaceutical opioid use was also obtained from a 
medication diary completed over a one-week period as part of the self-complete questionnaire 
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mailed to participants. Oral morphine equivalent (OME) daily doses (in mg) were estimated 
following consultation and synthesis of guidelines for conversion ratios from multiple international 
clinical expert groups (Nielsen et al., 2014). 
The Opioid Related Behaviours in Treatment (ORBIT) scale (Larance et al., 2014; Mattick et al., 2012) 
was designed to assist in the identiﬁcation of behaviours relating to pharmaceutical opioids that may 
reﬂect problems with treatment, including diversion and non-adherence. Those who reported 
endorsing any of the items in the past 3 months were deﬁned as having engaged in at least some 
form of nonadherence in that period. 
 
2.2. Statistical analyses 
 
Proportions and 95% conﬁdence intervals (95%CI) were estimated for the cannabis use variables. 
Odds ratios and their 95%CI from logistic regressions were calculated to compare those using 
cannabis for pain compared to the rest of the POINT cohort; and among cannabis users, to compare 
those who used only for recreational purposes, with those using for pain. For linear variables, Mann–
Whitney U or t-tests were completed. Multivariable regressions were run to examine independent 
correlates of cannabis use for pain. All analyses were conducted using STATA version 12.0. 
 
3. Results 
 
One in six of the cohort (16%) had used cannabis for pain relief, and 6% had done so in the previous 
month. A quarter (24%) reported that they would use it for pain relief if they had access to it (Table 
1). 
Among those using cannabis for pain, the average pain relief they reported they obtained from using 
cannabis was 70% (where 100% meant complete pain relief). In contrast, the average reported pain 
relief they reported receiving from their medications was 50%. Of those who had used cannabis for 
pain relief, n = 34 felt that cannabis provided 100% pain relief; only four of these reported that their 
medications gave them 100% pain relief (and among all those using cannabis for pain relief, n = 10 
reported 100% pain relief from their medications). 
Almost half (43%) of the sample had used cannabis for recreational purposes at some time. One in 
eight (12%) of the entire cohort had met criteria for an ICD-10 cannabis use disorder in their life time 
(Table 1). 
Those using cannabis for pain were younger and more likely to be male than those who did not 
(Table 2). Those using cannabis for pain were signiﬁcantly more likely to have met criteria for a range 
of other licit and illicit substance use disorders and to meet criteria for moderate or severe 
depression  and  generalised anxiety (Table 2). People who had used cannabis for pain were more 
likely to have back or neck problems, less likely to have arthritis, and had been living with pain for a 
signiﬁcantly longer period (156 months vs. 120 months) compared with those not using cannabis for 
pain. Those who had used cannabis for pain reported higher pain severity, greater interference from 
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and poorer coping  with pain, and more days out of role in the past year, compared to those who 
had not used (Table 2). People who had used cannabis for pain had been prescribed opioids for 
longer, were on higher opioid doses, were more likely to also have been prescribed benzodiazepines, 
and were more likely to be non-adherent with their prescribed opioids (Table 2). 
We also examined potential differences between those who used cannabis for pain, and those who 
had also used it only for recreational purposes (Table 3). By and large, the same correlates were 
found as for the overall comparisons. Those who used cannabis for pain were more likely than those 
who had only used it recreationally to report greater pain severity, greater pain interference, and 
poorer coping with pain. They also reported more days out of role in the past year and had higher 
levels of substance use disorders and mental health problems. However, there were no differences 
between the two groups in the median prescribed opioid dose, nor in non-adherent use of 
prescribed opioids. 
We additionally examined whether the association between cannabis use for pain, interference from 
pain, perceived pain relief reported from their medications and daily opioid dose, reﬂected greater  
pain  severity  (Table  4).  The  use  of  cannabis  for pain remained signiﬁcantly associated with 
greater interference from pain after controlling for reported pain severity (adjusted coefﬁcient 0.68; 
95%CI 0.43–0.94). The use of cannabis for pain was not associated with self-reported levels of pain 
relief from opioids or with opioid dose (Table 4). 
 
4. Discussion 
 
There is increasing debate about  the  use  of  cannabinoids for medicinal purposes, with jurisdictions 
in many countries increasingly choosing to decriminalise or legalise cannabis use, or to schedule 
synthetic cannabinoids for this purpose. In many countries, however, no cannabinoids are legally 
available for the treatment of any condition, including chronic non-cancer pain. 
Despite this, we found a high prevalence of cannabis use in a cohort of community-based people 
living with CNCP across Australia. In the general population, only 4.7% of those aged over 40 years 
had used cannabis in the past year (Australian Institute of Health and Welfare, 2011), compared with 
13% of our sample, which had a median age of 58 years. In this cohort, which had been prescribed 
opioids for CNCP, one in six had used cannabis for pain relief, and one in four would do so if they had 
access to the drug. Among those using cannabis for pain, subjective ratings of the relief achieved 
from cannabis compared very favourably with the same ratings of pain relief from opioids. 
The group using cannabis for pain was signiﬁcantly younger (median 48 years vs. 59 years), and had 
a more complex history, including greater reported pain and interference, and a higher likelihood of 
licit and illicit substance use problems, mental health problems and use of psychiatric medications.  
They  were taking signiﬁcantly higher doses of opioids and had done so for longer. 
The greater degree of pain severity and interference from pain among those using cannabis for pain 
have a number of possible explanations. Those using cannabis for pain were clearly a group who had 
greater problems across a number of domains including psychological distress and substance use 
problems, so the use of cannabis for pain may reﬂect those characteristics. Alternatively, the 
adjunctive use of cannabis for pain could reﬂect attempts to manage distress, given the experience 
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of greater interference from pain reported. It is impossible to decide between these possibilities in a 
cross-sectional study. Data from subsequent follow-ups of this cohort will provide an opportunity to 
explore whether there is an association between cannabis use for pain and a range of outcomes over 
time. 
Although the literature on cannabis and its impact on pain remains equivocal, ﬁndings here suggest 
that from a service user perspective, there is a signiﬁcant sub-population of people living with CNCP 
who see cannabis as a helpful adjunct to pain relief. This parallels the uncertainty about the value of 
long term opioid medication in chronic pain populations. Although few controlled studies have 
demonstrated effectiveness of opioids in CNCP, some patients strongly attest to the beneﬁts of 
opioids for pain relief and are resistant to opioid cessation. This resistance and testimony are  likely 
to be powerful drivers of the continued prescription of opioids by doctors treating patients with 
CNCP, particularly where other treatment strategies are difﬁcult to access or only have moderate 
beneﬁt. 
Medicine has had to address (and aims to minimise) the potential risks and harms of long term 
opioid use by chronic pain patients. A similar logic would suggest that doctors should aim to 
minimise potential harms from persistent cannabis use in a small but signiﬁcant population of 
chronic pain sufferers  who  continue to use cannabis adjunctively for pain relief. Although evidence 
from controlled clinical trials of cannabinoids for pain is lacking, the experience of individual patients 
suggests that there may be beneﬁts of cannabinoids for  some. 
 
4.1.  Strengths and limitations 
 
Some limitations of the study need to be considered. A clear strength of the study is the scope of our 
recruitment: 93% of Australian community pharmacies were approached, and a third assisted with 
recruitment; the geographic spread of participants was also similar to the spread of the Australian 
population (Campbell et al., 2014a). 
One issue, however, is the potential that we did not recruit a representative sample of people 
prescribed opioids for their chronic pain. In order to investigate this possibility, during recruitment 
we gathered additional data from a random sample of recruiting pharmacies (n = 71) on the 
characteristics of their opioid customers during the six week recruitment window of their 
involvement, and on the number of ﬂyers distributed to their customers. Of the total ﬂyers recorded 
as “distributed” by these pharmacies, 17% resulted in a contact with the study team from a 
customer. It is difﬁcult to know what proportion of the “distributed” ﬂyers were distributed to 
potentially eligible customers (and therefore what proportion of the ﬂyers were given to people who 
would not have contacted us as they would not be eligible) i.e. what proportion of potentially 
eligible customers decided not to contact us to be involved in the study. 
We additionally asked these pharmacists to collect data on the number and characteristics of 
customers purchasing opioids during the six-week recruitment window when they were recruiting 
for us. We found that of the total number of customers recorded as purchasing opioids in these 
pharmacies, 52% were female (the POINT cohort was 55% female); and 7% were 18–34 years, 55% 
35–64 years 
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and 38% 65+ years (vs. 5%, 62% and 33% respectively, in the POINT cohort). Of these customers, 
63% were prescribed oxycodone (vs. 62% in the POINT cohort), 16.5% prescribed morphine (vs. 15% 
in the POINT cohort), 21% prescribed fentanyl patches (vs. 15% in the POINT cohort) and 24% 
prescribed buprenorphine patches (vs. 21% in the POINT cohort). Although we cannot be sure that 
all the opioid customers recorded by these pharmacists had been taking these opioids for chronic 
pain, and for six weeks or more, the striking similarity in these demographic and opioid prescription 
characteristics is very reassuring. 
Another limitation is the potential biases that may be introduced by the reliance on self-report data. 
However, self-report is generally reliable when there are no disincentives for being honest (Chan, 
2009) and particularly enhances the validity of self-reported substance use (Darke, 1998). In this 
study all participants were assured that their responses would be de-identiﬁed and conﬁdential; 
further, any non-disclosure of cannabis use would serve to make any observed associations more 
conservative. Information on chronic medical illnesses or other health problems were not veriﬁed 
through patient records. Nonetheless, the rates of pain conditions and ﬁndings were similar to those 
in previous research with people living with chronic pain. 
Finally, we did not assess the amount of cannabis consumed, only frequency. Assessing the amount 
of cannabis consumed is a very challenging task for consumers of the drug. Attempts to quantify the 
amount of cannabis consumed in a “joint” or a “cone” have suggested that there is substantial 
variation across consumers in the amount of cannabis consumed in these measures, and additionally 
that consumers are not very accurate in estimating how much they are consuming in these 
measures (Norberg et al., 2012). There is increasing recognition, particularly in the US, that with the 
expansion of medicinal cannabis use for chronic pain, doctors need better understanding of the 
long-term effects of cannabis use, and of strategies to minimise its harms. This ultimately extends to 
considering the role of prescription pharmaceutical cannabinoids that can better regulate 
cannabinoid dose, composition, and routes of administration to avoid smoking (and its related 
harmful consequences) and also avoid dealing with illicit drug subcultures and markets to secure 
supply. 
In Australia, as in many countries, there is no regulatory framework for medicinal cannabinoid use. 
This means that cannabis use is effectively marginalised from any discussion or consideration of 
treatment strategies, despite being used by perhaps one in eight people living with CNCP. Health 
practitioners need a better understanding the potential harms and beneﬁts of cannabis use among 
patients they may be treating for CNCP. 
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